Meeting
2023 ASCO Annual Meeting
Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7).
Authors
Brian T. Hess
Division of Hematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC
Brian T. Hess , Melhem M. Solh , Mitul Gandhi , Ying Wang , Yajuan Qin , Eric Yu , Pier Luigi Zinzani , Graham P. Collins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT04970901
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS7581)
DOI
10.1200/JCO.2023.41.16_suppl.TPS7581
Abstract #
TPS7581
Poster Bd #
130b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
First Author: Philippe Armand
Poster
2022 ASCO Annual Meeting
Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).
First Author: Jose Caetano Villasboas
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe